The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group.
about
The Hawthorne Effect: a randomised, controlled trialThe cholinergic hypothesis of Alzheimer's disease: a review of progressLeveraging the cortical cholinergic system to enhance attentionIs donepezil effective for treating Alzheimer's disease?Placebo effects: clinical aspects and neurobiologyNeural stem cells: involvement in adult neurogenesis and CNS repair"Closing-in" phenomenon in Alzheimer's disease and subcortical vascular dementiaSystematic Review: Representativeness of Participants in RCTs of Acetylcholinesterase InhibitorsEfficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trialProbing peripheral and central cholinergic system responsesEffects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trialThe timing of drug funding announcements relative to elections: a case study involving dementia medicationsLong-Term Cholinesterase Inhibitor Therapy for Alzheimer's Disease: Practical Considerations for the Primary Care PhysicianTreatment guidelines for Alzheimer's disease: redefining perceptions in primary care.Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials.Alzheimer's disease in the United Kingdom: developing patient and carer support strategies to encourage care in the community.Diagnosis of dementia and treatment of Alzheimer's disease. Pharmacologic management of disease progression and cognitive impairmentRapid appraisal of barriers to the diagnosis and management of patients with dementia in primary care: a systematic review.Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease.Acetylcholinesterase inhibitors in Alzheimer's disease.The prediction and prevention of Alzheimer's disease--towards a research agendaNorth of England evidence based guidelines development project: guideline for the primary care management of dementiaNot playing with a full DEC: why development and evaluation committee methods for appraising new drugs may be inadequatePurpuric rash with donepezil treatmentCholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.Treating patients with moderate to severe Alzheimer's disease: implications of recent pharmacologic studies.Advances in the pharmacotherapy of Alzheimer's disease.Prevalence of potentially reversible dementias and actual reversibility in a memory clinic cohortCauses of Alzheimer's diseaseWhy should primary care physicians know about the genetics of dementia?The value of clock drawing in identifying executive cognitive dysfunction in people with a normal Mini-Mental State Examination score.Drugs for dementia: the first year. An audit of prescribing practice.Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance.Long-term care eligibility criteria for people with Alzheimer's diseaseThe safety and tolerability of donepezil in patients with Alzheimer's disease.Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses.Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administrationConcurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple dosesDonepezil in Alzheimer's disease: From conventional trials to pharmacogenetics
P2860
Q21261930-998444AA-E2B3-4089-ABD1-ABF3E691C279Q22242019-9EBD1E94-F858-4132-8719-713B258095CCQ24598925-0FA4B95A-C12A-4B4F-BCE9-4803823DFB89Q24642471-8535DF2C-6561-43CC-A3FF-63AFF78ECA13Q24653735-15814319-7BAA-4811-BFA6-CA41317786BAQ24656935-72AA6866-3D00-4CFB-B045-6E96CB63E4C7Q24796717-368E32F1-ADB7-4007-9C17-28EF554DF575Q26863383-8930202A-BA51-4CC6-A2AF-827D02A57FFEQ28343193-01A02F43-A90A-4FF7-A789-873011943D10Q28344836-BCF19F45-8975-4451-894E-4CD6A204843BQ28362149-5F6CD923-1598-4739-B091-61395063253DQ28486951-051CDCDA-5207-4892-AD71-5891751A2F33Q30433785-3F0AB0BD-CA22-4C42-AC98-B38C2B84AA37Q30443975-1A2D4C9D-9A6D-4917-A358-1EF8C5E0B9ADQ33160127-72CDCDF4-36D9-4E49-BC8B-E905D156B52BQ33578920-D09FF321-BB52-4F7E-92B0-06DE4C9ED1DCQ33601574-9D2D3FEF-EEA6-48B6-A921-B5DC5490D808Q33622849-FEF8C8E4-2ACD-405A-BB64-655B286728CCQ33662471-301AA4BC-C916-4AF3-9DF2-D87D81CFB45EQ33785568-78C25576-C331-4B03-ACA9-4FF8D60DBBCCQ33787542-B8171E60-54BB-43E5-9504-7CB0EC72706FQ33791951-3C155356-5110-4FD2-B71F-C6F96BDABB49Q33795965-42698E5F-FA00-4AC9-8E48-9C7AB0B0104BQ33838983-51F271B4-60E6-4F87-B0CB-B14E78A4139EQ33912750-1F5F7BFE-4DFC-448A-81A1-0BA877CAF85FQ33928316-2FD31806-86EE-4EAB-B6A1-F2F93AAD05EBQ34011160-FC867BBA-4E2C-4386-BB4B-6F5A42B6370AQ34029725-20E327EC-0EF0-4827-B510-942DF063E667Q34037204-09A72309-530A-4DFA-AD27-CD26B8A69FD4Q34115616-8165DA25-E2EB-4D32-9D29-633AA05B801AQ34133658-64921D3C-AD4B-4701-B9A9-FAED82C65ABCQ34150502-CC90E5C9-0047-4EE3-AFB5-AA5C1C457DD3Q34209573-7CA6EA92-8CFF-4583-924B-1BA83780BA15Q34326803-4D7812B9-DA9B-4B20-91B5-217A56711044Q34552035-E3B062D7-2AE9-45A1-A0A4-ED5F8F81C51EQ34648742-E5C781DE-35F2-4D37-A68E-6C220C25ECD5Q34755433-7D99F3E7-79C0-4DA5-865F-9A3B6BBF3063Q34755442-6D34652D-78CB-492F-8996-587669926767Q34755454-72798F9A-90E4-4DB5-A118-D6A04AFD1995Q34965949-CCE6F904-8E7F-4D03-8FA7-4F9C359DF7DA
P2860
The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
The efficacy and safety of don ...... al. The Donepezil Study Group.
@en
The efficacy and safety of don ...... al. The Donepezil Study Group.
@nl
type
label
The efficacy and safety of don ...... al. The Donepezil Study Group.
@en
The efficacy and safety of don ...... al. The Donepezil Study Group.
@nl
prefLabel
The efficacy and safety of don ...... al. The Donepezil Study Group.
@en
The efficacy and safety of don ...... al. The Donepezil Study Group.
@nl
P1476
The efficacy and safety of don ...... ial. The Donepezil Study Group
@en
P2093
Friedhoff LT
P304
P577
1996-11-01T00:00:00Z